Lishen Pharmaceutical: Net profit for 2025 increased 125.59% year-over-year; proposes 10-for-2 stock split with 6 yuan dividend

MetaMuskRat · 2026-03-24T12:30:25+00:00

People Finance News on March 24 reported that Lishen Pharmaceutical (002393) released its annual report on March 24. In 2025, it achieved operating revenue of 1.392 billion yuan, representing a year-over-year increase of 4.18%; net profit attributable to parent company shareholders was 416 million yuan, a year-over-year increase of 125.59%; basic earnings per share was 1.62 yuan. The company plans to issue 2 bonus shares for every 10 shares held and distribute a cash dividend of 6 yuan per share (including tax).

MetaMuskRat

2026-03-24 12:30:25

People’s Financial News, March 24 — Lisheng Pharmaceutical (002393) released its annual report on March 24. By 2025, the company aims to achieve operating revenue of 1.392 billion yuan, a year-on-year increase of 4.18%; net profit attributable to shareholders of the parent company is expected to be 416 million yuan, a year-on-year increase of 125.59%; basic earnings per share are 1.62 yuan. The company plans to distribute 2 bonus shares for every 10 shares and pay a cash dividend of 6 yuan (tax included).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.